

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER MEASURES.

PRESS RELEASE

Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm

Lund, Sweden June 7, 2024. Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA) on April 12, 2024, announced that the board of directors had resolved on a directed share issue of 12,780,000 ordinary shares, divided into two tranches whereby the first tranche consisted of 10,474,740 ordinary shares (the "**First Tranche**") and the second tranche consisted of 2,305,260 ordinary shares (the "**Second Tranche**"), to a number of Swedish and international institutional investors (the First Tranche and the Second Tranche are jointly referred to as the "**Directed Share Issue**").

A prospectus regarding admission to trading of the newly issued ordinary shares in the Second Tranche on Nasdaq Stockholm has been approved and registered with the Swedish Financial Supervisory Authority (Sw. *Finansinspektionen*) and is available on the Company's website (www.hansabiopharma.com) and will be available on the SFSA's website. Trading in the ordinary shares issued in the Second Tranche is expected to commence on Nasdaq Stockholm on or around June 12, 2024.

The information was submitted for publication, through the agency of the contact persons below, on June 7, 2024 at 09:15 (CEST).

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on [LinkedIn](https://www.linkedin.com/company/hansa-biopharma).

©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.